Nanomedicine for the treatment of Alzheimer's disease

Nanomedicine

Volumn 10, Issue 7, 2015, Pages 1203-1218

  Gregori, Maria ^a   Masserini, Massimo ^a   Mancini, Simona ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Alzheimer's disease; amyloid peptide; blood brain barrier; nanomedicine; nanoparticles

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; CHITOSAN; GOLD NANOPARTICLE; LIPOSOME; MAGNETITE; SOLID LIPID NANOPARTICLE; NANOPARTICLE;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY BASEMENT MEMBRANE; CAPILLARY ENDOTHELIAL CELL; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; EXOSOME; HUMAN; IMMUNOTHERAPY; NANOMEDICINE; NANOTECHNOLOGY; NEUROTOXICITY; POLYMERIZATION; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; METABOLISM; PATHOLOGY; PROCEDURES; PROTEIN AGGREGATION, PATHOLOGICAL; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; PROTEIN AGGREGATION, PATHOLOGICAL;

EID: 84929083605     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.206     Document Type: Article

References (89)

1. Gaugler J, James B, Johnson T, Scholz K, Weuve J. Alzheimer's disease facts and figures 2013. Alzheimer's Disease Association on line source. www.alz.org/downloads/facts-figures-2013.pdf
2. Ittner LM, Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12(2), 65-72 (2011).
3. Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J. Alzheimers Dis. 19(1), 311-323 (2010).
4. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8(2), 101-112 (2007).
5. Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer's disease. Ther. Adv. Neurol. Disord. 6(1), 19-33 (2013).
6. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int. J. Clin. Pract. 59(7), 817-822 (2005).
7. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 335(1), 75-96 (2009).
8. Biswas S, Torchilin VP. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug. Deliv. Rev. 66, 26-41 (2014).
9. Mathew A, Fukuda T, Nagaoka Y et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's Disease. PLoS ONE 7(3), e32616 (2012).
10. Cheng KK, Yeung CF, Ho SW, Chow SF, Chow AH, Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J. 15(2), 324-336 (2013).
11. Liu Z, Gao X, Kang T et al. B6 Peptide-Modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug. Chem. 24(6), 997-1007 (2013).
12. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 1200, 159-168 (2008).
13. Mittal G, Carswell H, Brett R, Currie S, Kumar MN. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer's pathology. J. Control. Release 150(2), 220-228 (2011).
14. Yu Y, Jiang X, Gong S, Feng L, Zhong Y, Pang Z. The proton permeability of self-assembled polymersomes and their neuroprotection by enhancing a neuroprotective peptide across the blood-brain barrier after modification with lactoferrin. Nanoscale 6(6), 3250-3258 (2014).
15. Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine 8(2), 250-260 (2012).
16. Le Droumaguet B, Nicolas J, Brambilla D et al. Versatile and efficient targeting using a single nanoparticulate platform: application to cancer and Alzheimer's disease. ACS Nano 6(7), 5866-5879 (2012).
17. Zhang C, Chen J, Feng C, Shao X et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease. Int. J. Pharm. 461(1-2), 192-202 (2014).
18. Zhang C, Wan X, Zheng X et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. Biomaterials 35(1), 456-465 (2014).
19. Liu G, Men P, Kudo W, Perry G, Smith MA. Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci. Lett. 455(3), 187-190 (2009).
20. Baysal I, Yabanoglu-Ciftci S, Tunc-Sarisozen Y, Ulubayram K, Ucar G. Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils. J. Neural. Transm. 120(6), 903-910 (2013).
21. Puras G, Salvador A, Igartua M, Hernández RM, Pedraz JL. Encapsulation of Aβ (1-15) in PLGA microparticles enhances serum antibody response in mice immunized by subcutaneous and intranasal routes. Eur. J. Pharm. Sci. 44(3), 200-206 (2011).
22. Liu Y, Liu Z, Wang Y et al. Investigation of the performance of PEG-PEI/ROCK-II-siRNA complexes for Alzheimer's disease in vitro. Brain Res. 1490, 43-51 (2013).
23. Re F, Cambianica I, Zona C et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomedicine 7(5), 551-559 (2011).
24. Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG. Multifunctional nanoliposomes with curcumine lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur. J. Med. Chem. 80, 175-183 (2014).
25. Sancini G, Gregori M, Salvati E et al. Functionalization with TAT-peptide enhances blood-brain barrier crossing in vitro of nanoliposomes carrying a curcumin-derivative to bind Amyloid-b peptide. J. Nanomed. Nanotechol. 4(3), 171-178 (2013).
26. Mourtas S, Canovi M, Zona C et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1- 42 peptide. Biomaterials 32(6), 1635-1645 (2011).
27. Taylor M, Moore S, Mourtas S et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide. Nanomedicine 7(5), 541-550 (2011).
28. Salvati E, Re F, Sesana S et al. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: the chemical design affects the permeability across an in vitro model. Int. J. Nanomedicine 8, 1749-1758 (2013).
29. Bana L, Minniti S, Salvati E et al. Liposomes bifunctionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain barrier: Implications for therapy of Alzheimer disease. Nanomedicine 10(7), 1583-1590 (2014).
30. Gobbi M, Re F, Canovi M et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31(25), 6519-6529 (2010).
31. Ahyayauch H, Raab M, Busto JV et al. Binding of β-amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. Biophys. J. 103(3), 453-463 (2012).
32. Balducci C, Mancini S, Minniti S et al. Multi-functional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. J. Neurosci.34(42), 14022-14031 (2014).
33. Tanifum EA, Dasgupta I, Srivastava M et al. Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice. PLoS ONE 7(10), e48515 (2012).
34. Airoldi C, Mourtas S, Cardona F et al. Nanoliposomes presenting on surface a cis-glycofused benzopyran compound display binding affinity and aggregation inhibition ability towards Amyloid β1-42 peptide. Eur. J. Med. Chem. 85, 43-50 (2014).
35. Canovi M, Markoutsa E, Lazar AN et al. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in postmortem tissue. Biomaterials 32(23), 5489-5497 (2011).
36. Mufamadi MS, Choonara YE, Kumar P et al. Surface-engineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with β-amyloid aggregates of Alzheimer's disease. Pharm. Res. 29(11), 3075-3089 (2012).
37. Smith A, Giunta B, Bickford PC, Fountain M, Tan J, Shytle RD. Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease. Int. J. Pharm. 389(1-2), 207-212 (2010).
38. Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model. J. Drug Target 21(3), 300-311 (2013).
39. Elmizadeh H, Khanmohammadi M, Ghasemi K, Hassanzadeh G, Nassiri-Asl M, Garmarudi AB. Preparation and optimization of chitosan nanoparticles and magnetic chitosan nanoparticles as delivery systems using Box-Behnken statistical design. J. Pharm. Biomed. Anal. 80, 141-146 (2013).
40. Songjiang Z, Lixiang W. Amyloid-beta associated with chitosan nano-carrier has favorable immunogenicity and permeates the BBB. AAPS PharmSciTech. 10(3), 900-905 (2009).
41. Wilson B, Samanta MK, Santhi K, Sampath Kumar KP, Ramasamy M, Suresh B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. J. Neurosci. Methods 177(2), 427-433 (2009).
42. Luppi B, Bigucci F, Corace G et al. Albumin nanoparticles carrying cyclodextrins for nasal delivery of the anti-Alzheimer drug tacrine. Eur. J. Pharm. Sci. 44(4), 559-565 (2011).
43. Prades R, Guerrero S, Araya E et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials 33(29), 7194-7205 (2012).
44. Kogan MJ, Bastus NG, Amigo R et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 6(1), 110-115 (2006).
45. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29(4), 341-345 (2011).
46. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J. Control. Release 152(2), 208-231 (2011).
47. Brambilla D, Le Droumaguet B, Nicolas J et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 7(5), 521-540 (2011).
48. Service RF. Nanotechnology. Nanoparticle Trojan horses gallop from the lab into the clinic. Science 330(6002), 314-315 (2010).
49. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104(1), 29-45 (2004).
50. Weiss N, Miller F, Cazaubon S, Couraud P-O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta 1788(4), 842-857 (2009).
51. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005).
52. Antimisiaris SG, Kallinteri P, Fatouros DG. Liposomes and drug delivery. In: Pharmaceutical Manufacturing Handbook: Production and Processes. Gad SC (Ed.). John Wiley & Sons, Inc., NJ, USA, Chapter 13 (2007).
53. Gastaldi L, Battaglia L, Peira E et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur. J. Pharm. Biopharm. 87, 433-444 (2014).
54. Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv. Drug Deliv. Rev. 64(7), 701-705 (2012).
55. Sousa F, Mandal S, Garrovo C et al. Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale 2(12), 2826-2834 (2010).
56. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42(6), 463-478 (2003).
57. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochemistry. Article ID 238428 (2013).
58. Krol S. Challenges in drug delivery to the brain: nature is against us. J. Control. Release 164(2), 145-155 (2012).
59. Yu Y, Pang Z, Lu W, Yin Q, Gao H, Jiang X. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Pharm. Res. 29(1), 83-96 (2012).
60. Kreuter J, Shamenkov D, Petrov V. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 10(4), 317-325 (2002).
61. Chonpathompikunlert P, Wattanathorn J, Muchimapura S. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. Food Chem. Toxicol. 48(3), 798-802 (2010).
62. Keana T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 62(1), 3-11 (2010).
63. Türker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm. World Sci. 26(3), 137-142 (2004).
64. Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Recent advances in PEG-PLA block copolymer nanoparticles. Int. J. Nanomedicine 5, 1057-1065 (2010).
65. Matsuzaki K. Physicochemical interactions of amyloid betapeptide with lipid bilayers. Biochim. Biophys. Acta 1768(8), 1935-1942 (2007).
66. Brambilla D, Verpillot R, Le Droumaguet B et al. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. ACS Nano 6(7), 5897-5908 (2012).
67. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280(7), 5892-5901 (2005).
68. Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23), 6641-6648 (2000).
69. Delrieu J, Ousset PJ, Caillaud C, Vellas B. Clinical Trials in Alzheimer's disease: immunotherapy approaches. J. Neurochem. 120, 186-193 (2012).
70. Evin G, Sernee MF, Masters CL. Inhibition of gammasecretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20(5), 351-372 (2006).
71. Luo Y, Bolon B, Kahn S et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat. Naurosci. 4(3), 231-232 (2001).
72. Herskowitz JH, Seyfried NT, Gearing M et al. Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-beta production. J. Biol. Chem. 286(8), 6117-6127 (2011).
73. Fernandez JW, Rezai-Zadeh K, Obregon D, Tan J. EGCG functions through estrogen receptor-mediated activation of ADAM10 in the promotion of non-amyloidogenic processing of APP. FEBS Lett. 584(19), 4259-4267 (2010).
74. Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH, Dou QP. Recent advances on tea polyphenols. Front. Biosci. (Elite Ed.) 4, 111-131 (2012).
75. Win-Shwe TT, Fujimaki H. Nanoparticles and neurotoxicity. Int. J. Mol. Sci. 12(9), 6267-6280 (2011).
76. Karmakar A, Zhang Q, Zhang Y. Neurotoxicity of nanoscale materials. Yao Wu Shi Pin Fen Xi 22(1), 147-160 (2014).
77. Hu K, Li J, Shen Y et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release 134(1), 55-61 (2009).
78. Lasagna-Reeves C, Gonzalez-Romero D, Barria MA et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem. Biophys. Res. Commun. 393(4), 649-655 (2010).
79. Guerrero S, Araya E, Fiedler JL et al. Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide. Nanomedicine 5(6), 897-913 (2010).
80. Koch F, Möller AM, Frenz M, Pieles U, Kuehni-Boghenbor K, Mevissen M. An in vitro toxicity evaluation of gold-, PLLA- and PCL-coated silica nanoparticles in neuronal cells for nanoparticle-assisted laser-tissue soldering. Toxicol. In vitro 28(5), 990-998 (2014).
81. Hutter E, Boridy S, Labrecque S et al. Microglial response to gold nanoparticles. ACS Nano 4(5), 2595-2606 (2010).
82. Lettiero B, Andersen AJ, Hunter AC, Moghimi SM. Complement system and the brain: selected pathologies and avenues toward engineering of neurological nanomedicines. J. Control. Release 161(2), 283-289 (2012).
83. Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease. Brain Res. 645(1-2), 78-84 (1994).
84. Yasojima K, Schwab C, McGeer EG, McGeer PL. Upregulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154(3), 927-936 (1999).
85. Donev R, Koseva N, Petrov P, Kowalczuk A, Thome J. Characterisation of different nanoparticles with a potential use for drug delivery in neuropsychiatric disorders. World J. Biol. Psychiatry 12(Suppl. 1), 44-51 (2011).
86. Alving CR. Natural antibodies against phospholipids and liposomes in human. Biochem. Soc. Trans. 12(2), 342-344 (1984).
87. Bradley AJ, Maurer-Spurej E, Brooks DE, Devine DV. Unusual electrostatic effects on binding to C1q to anionic liposomes: role of anionic phospholipid domains and their line tension. Biochemistry 38(25), 8112-8123 (1999).
88. Devine DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: implications for liposome survival studies. Biochim. Biophys. Acta 1191(1), 43-51 (1994).
89. Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 63(12), 1020-1030 (2011).